Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy

J. K V Willson, R. F. Ozols, B. J. Lewis, R. C. Young

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although the successful use of systemic chemotherapy in the management of the GTDs is well established, two areas remain that require further investigation. First, the sensitive assay for hCG titer may allow a more precise tailoring of established drug therapy. Such tailoring, it is hoped, would reduce the toxicity of current treatment by allowing fewer courses of therapy. Second, a group of patients at high risk with central nervous system or hepatic metastases has been defined. New treatment approaches with combination chemotherapy regimens have proved beneficial even in previously refractory cases. The development of even more successful regimens in combination with other modalities such as radiation therapy appears hopeful. It seems not unreasonable to consider all patients with a trophoblastic neoplasm to be potentially curable with current therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)81-98
Number of pages18
JournalAmerican Journal of Obstetrics and Gynecology
Volume141
Issue number1
StatePublished - 1981

Fingerprint

Drug Therapy
Neoplasms
Trophoblastic Neoplasms
Therapeutics
Combination Drug Therapy
Radiotherapy
Central Nervous System
Neoplasm Metastasis
Liver

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy. / Willson, J. K V; Ozols, R. F.; Lewis, B. J.; Young, R. C.

In: American Journal of Obstetrics and Gynecology, Vol. 141, No. 1, 1981, p. 81-98.

Research output: Contribution to journalArticle

Willson, J. K V ; Ozols, R. F. ; Lewis, B. J. ; Young, R. C. / Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy. In: American Journal of Obstetrics and Gynecology. 1981 ; Vol. 141, No. 1. pp. 81-98.
@article{04f008244ac34ffabe663b593bc9bf90,
title = "Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy",
abstract = "Although the successful use of systemic chemotherapy in the management of the GTDs is well established, two areas remain that require further investigation. First, the sensitive assay for hCG titer may allow a more precise tailoring of established drug therapy. Such tailoring, it is hoped, would reduce the toxicity of current treatment by allowing fewer courses of therapy. Second, a group of patients at high risk with central nervous system or hepatic metastases has been defined. New treatment approaches with combination chemotherapy regimens have proved beneficial even in previously refractory cases. The development of even more successful regimens in combination with other modalities such as radiation therapy appears hopeful. It seems not unreasonable to consider all patients with a trophoblastic neoplasm to be potentially curable with current therapeutic modalities.",
author = "Willson, {J. K V} and Ozols, {R. F.} and Lewis, {B. J.} and Young, {R. C.}",
year = "1981",
language = "English (US)",
volume = "141",
pages = "81--98",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Current status of therapeutic modalities for treatment of gynecologic malignancies with emphasis on chemotherapy

AU - Willson, J. K V

AU - Ozols, R. F.

AU - Lewis, B. J.

AU - Young, R. C.

PY - 1981

Y1 - 1981

N2 - Although the successful use of systemic chemotherapy in the management of the GTDs is well established, two areas remain that require further investigation. First, the sensitive assay for hCG titer may allow a more precise tailoring of established drug therapy. Such tailoring, it is hoped, would reduce the toxicity of current treatment by allowing fewer courses of therapy. Second, a group of patients at high risk with central nervous system or hepatic metastases has been defined. New treatment approaches with combination chemotherapy regimens have proved beneficial even in previously refractory cases. The development of even more successful regimens in combination with other modalities such as radiation therapy appears hopeful. It seems not unreasonable to consider all patients with a trophoblastic neoplasm to be potentially curable with current therapeutic modalities.

AB - Although the successful use of systemic chemotherapy in the management of the GTDs is well established, two areas remain that require further investigation. First, the sensitive assay for hCG titer may allow a more precise tailoring of established drug therapy. Such tailoring, it is hoped, would reduce the toxicity of current treatment by allowing fewer courses of therapy. Second, a group of patients at high risk with central nervous system or hepatic metastases has been defined. New treatment approaches with combination chemotherapy regimens have proved beneficial even in previously refractory cases. The development of even more successful regimens in combination with other modalities such as radiation therapy appears hopeful. It seems not unreasonable to consider all patients with a trophoblastic neoplasm to be potentially curable with current therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0019487015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019487015&partnerID=8YFLogxK

M3 - Article

VL - 141

SP - 81

EP - 98

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -